BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. Int J Mol Sci. 2020;21:5254. [PMID: 32722100 DOI: 10.3390/ijms21155254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Yang YJ, Kim DJ. An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia. Int J Mol Sci 2021;22:2604. [PMID: 33807573 DOI: 10.3390/ijms22052604] [Reference Citation Analysis]
2 Nishikawa H, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Sarcopenia and Frailty in Liver Cirrhosis. Life (Basel) 2021;11:399. [PMID: 33925660 DOI: 10.3390/life11050399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Nishikawa H, Nakamura S, Miyazaki T, Kakimoto K, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance. J Clin Med 2021;10:4214. [PMID: 34575326 DOI: 10.3390/jcm10184214] [Reference Citation Analysis]
4 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact. Int J Mol Sci 2021;22:1917. [PMID: 33671926 DOI: 10.3390/ijms22041917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Micó-Carnero M, Rojano-Alfonso C, Álvarez-Mercado AI, Gracia-Sancho J, Casillas-Ramírez A, Peralta C. Effects of Gut Metabolites and Microbiota in Healthy and Marginal Livers Submitted to Surgery. Int J Mol Sci 2020;22:E44. [PMID: 33375200 DOI: 10.3390/ijms22010044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Ren X, Hao S, Yang C, Yuan L, Zhou X, Zhao H, Yao J. Alterations of intestinal microbiota in liver cirrhosis with muscle wasting. Nutrition 2021;83:111081. [PMID: 33348106 DOI: 10.1016/j.nut.2020.111081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Ushiro K, Nishikawa H, Matsui M, Ogura T, Takeuchi T, Goto M, Nakamura S, Kakimoto K, Miyazaki T, Fukunishi S, Asai A, Ohama H, Yokohama K, Yasuoka H, Higuchi K. Comparison of SARC-F Score among Gastrointestinal Diseases. J Clin Med 2021;10:4099. [PMID: 34575208 DOI: 10.3390/jcm10184099] [Reference Citation Analysis]
8 Nishikawa H, Yoh K, Enomoto H, Nishimura T, Nishiguchi S, Iijima H. Factors Associated With Longitudinal QOL Change in Patients With Chronic Liver Diseases. In Vivo 2021;35:2451-6. [PMID: 34182530 DOI: 10.21873/invivo.12524] [Reference Citation Analysis]
9 Hari A. Muscular abnormalities in liver cirrhosis. World J Gastroenterol 2021; 27(29): 4862-4878 [PMID: 34447231 DOI: 10.3748/wjg.v27.i29.4862] [Reference Citation Analysis]
10 Marasco G, Dajti E, Ravaioli F, Brocchi S, Rossini B, Alemanni LV, Peta G, Bartalena L, Golfieri R, Festi D, Colecchia A, Renzulli M. Clinical impact of sarcopenia assessment in patients with liver cirrhosis. Expert Rev Gastroenterol Hepatol 2021;15:377-88. [PMID: 33196344 DOI: 10.1080/17474124.2021.1848542] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Tamai Y, Iwasa M, Eguchi A, Shigefuku R, Kamada Y, Miyoshi E, Takei Y. Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy. JGH Open 2021;5:827-30. [PMID: 34263080 DOI: 10.1002/jgh3.12596] [Reference Citation Analysis]
12 Nishikawa H, Yoh K, Enomoto H, Nishiguchi S, Iijima H. Dynapenia Rather Than Sarcopenia Is Associated with Metabolic Syndrome in Patients with Chronic Liver Diseases. Diagnostics (Basel) 2021;11:1262. [PMID: 34359344 DOI: 10.3390/diagnostics11071262] [Reference Citation Analysis]